STOCK TITAN

CorMedix Inc. - $CRMD STOCK NEWS

Welcome to our dedicated page for CorMedix news (Ticker: $CRMD), a resource for investors and traders seeking the latest updates and insights on CorMedix stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CorMedix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CorMedix's position in the market.

Rhea-AI Summary
CorMedix to present at H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
-
Rhea-AI Summary
CorMedix Inc. receives U.S. Patent for catheter lock solution, extending intellectual property protection until 2042.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. (CRMD) provided an update on recent business events, including the acceptance for filing of its DefenCath NDA by the FDA and a strategic initiative with Boston Medical Center. The company also announced financial results for the second quarter and six months ended June 30, 2023, and completed an equity offering generating net proceeds of approximately $43.2 million. The company's cash and short-term investments at June 30, 2023, amounted to $52.4 million, with pro forma cash and short-term investments of approximately $95 million including net proceeds from the equity offering. The company recorded a net loss of $11.3 million for the second quarter of 2023, compared with a net loss of $7.6 million in the second quarter of 2022, and a net loss of $21.8 million for the six months ended June 30, 2023, compared with a net loss of $14.6 million in the first half of 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) to Report Q2 2023 Financial Results and Host Corporate Update Conference Call on August 8, 2023. The biopharmaceutical company will focus on developing and commercializing therapeutic products for life-threatening conditions and diseases. The financial report will be released before the market opens, followed by a conference call at 8:30am Eastern Time. Investors can join the call using the provided domestic and international numbers or through the webcast link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences earnings
-
Rhea-AI Summary
CorMedix Inc. announces pricing of underwritten public offering of common stock and pre-funded warrants, expected to raise approximately $40 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.29%
Tags
Rhea-AI Summary
CorMedix announces that the resubmission of the NDA for DefenCath has been accepted by the FDA. The PDUFA target action date is November 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
-
Rhea-AI Summary
CorMedix Inc. announces a strategic initiative with Boston Medical Center to enhance patient safety and reduce health disparities in dialysis patients at risk for bloodstream infections. The initiative aims to evaluate the use of a novel antimicrobial catheter lock solution to reduce the incidence of infections in patients receiving dialysis through a central venous catheter. The goal is to increase healthy outcomes for patients disproportionately impacted by these infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. will be presenting and participating in investor meetings at the Jefferies Healthcare Conference in New York on June 7-9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
Rhea-AI Summary
CorMedix Inc. has resubmitted the New Drug Application for DefenCath to the FDA, signaling progress towards potential approval in 2023. The company aims to reduce the risk of infections in patients receiving hemodialysis via central venous catheters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.4%
Tags
none
CorMedix Inc.

Nasdaq:CRMD

CRMD Rankings

CRMD Stock Data

281.39M
54.43M
1.01%
34.12%
15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BERKELEY HEIGHTS

About CRMD

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.